One century ago, microscopic analysis of brain tissue from a single patient, Auguste Deter, established a link between amyloid plaques, neurofibrillary tangles, and severe memory loss^[@R1]^. Amyloid plaques were, in fact, first described by Blocq and Marinesco in 1892, in patients with epilepsy^[@R2]^. Alzheimer's disease (AD) and epilepsy both impair cognition and manifest overlapping patterns of cellular neurodegeneration and hypometabolism in the temporal lobe^[@R3]^. Despite extraordinary advances in the molecular pathology of AD^[@R4]^, the structural basis for the early fluctuating course of cognitive decline in AD remains elusive and cannot be explained from purely microscopic or macroscopic pathological standpoints. Correlation of cognitive deficits with amyloid plaque load is weak^[@R5]^, comparable brain atrophy can be seen in cognitively normal adults^[@R6]^ and in non-dementing diseases (including epilepsy)^[@R7]^, and a fluctuating course is not easily explained by a monotonic process of progressive cell death. Interneurons are among the first to die in AD mesial temporal cortex^[@R8]^, however, and the ensuing degradation of synaptic connectivity and circuit remodeling could disrupt network oscillations that contribute to memory storage and retrieval. Intermittent temporal lobe dysrhythmia could therefore account for early fluctuations in cognition in AD patients. Here, we used intracranial electrodes inserted through the foramen ovale (FO) and positioned adjacent to the mesial temporal lobe (mTL)^[@R9]^ to directly assess, for the first time, mTL activity in two patients with AD and fluctuating cognition.

The first patient examined was a 67 year-old woman with no seizure history who developed cognitive decline over one year, punctuated by confusional episodes described as hours of repetitive questioning and garbled speech that required days for full recovery. Neuropsychological testing demonstrated amnestic mild cognitive impairment. Additional clinical details are reported in the [Supplementary Information](#SD1){ref-type="supplementary-material"}.

Brain MRI showed diffuse atrophy, and ^18^FDG-PET demonstrated left temporoparietal hypometabolism ([Supp. Figure 1a,b](#SD1){ref-type="supplementary-material"}). A 35-minute scalp EEG obtained during sleep showed normal sleep architecture including spindles and K-complexes, and no evidence of focal slowing or epileptiform discharges. CSF analysis showed an amyloid-tau index of 0.44 (\<1.0 abnormal) and a phosphorylated tau level of 95.9 pg/mL (\>61 abnormal), consistent with a diagnosis of AD. Genetic testing revealed *APOE3/4* alleles but no exome variants in three known familial AD genes ([Supp. Figure 2](#SD1){ref-type="supplementary-material"}). On continuous video-EEG monitoring, left temporal sharp waves were seen at a rate of \~2/hour during wakefulness and \~40--70/hour during sleep. Rare right temporal sharp waves also occurred during sleep (\~5/hour). Based on a high index of suspicion for occult seizures, the patient was implanted with bilateral FO electrodes targeting the mTL ([Figure 1a](#F1){ref-type="fig"}). Intracranial recordings from these electrodes revealed abundant mTL spiking (\~400/hour during wakefulness and up to \~850/hour during sleep), with 85% of spikes arising from the left mTL. The majority (95%) of spikes detected on FO electrodes were not evident on scalp EEG ([Figure 1b](#F1){ref-type="fig"}). During the first of 12 hours of recording, the patient had three subclinical seizures arising from the left mTL, all occurring during sleep ([Figure 1c](#F1){ref-type="fig"}). Scalp EEG during these seizures showed no ictal activity. One seizure was associated with awakening from sleep, while the others had no overt clinical manifestations. The patient was treated with levetiracetam, a common anti-epileptic drug that has been shown to reduce abnormal spiking activity in animal models of AD^[@R10]^ and to reduce hippocampal hyperactivity in humans with amnestic mild cognitive impairment^[@R11]^. Levetiracetam binds to SV2A^[@R12]^, a synaptic vesicle protein that regulates neurotransmitter release, though the exact mechanism of levetiracetam's anticonvulsant effect is unknown. After starting levetiracetam (1500mg/day), no further seizures were captured on FO electrodes over the following 48 hours prior to their removal, and spike frequency was reduced by 65%. Twelve months later, she reported one spell of confusion following several consecutively missed doses of levetiracetam. Repeat neuropsychological testing showed mild progression of her cognitive deficits.

The second patient included in this study was a 58 year-old woman with no seizure history, initially evaluated for gradual cognitive decline, including repetitive questioning, misplacing objects, and social withdrawal. Within 5 years, she had severe dementia (additional clinical details are reported in the [Supplementary Information](#SD1){ref-type="supplementary-material"}). Brain MRI demonstrated diffuse atrophy ([Supp. Figure 1c](#SD1){ref-type="supplementary-material"}), and CSF showed an amyloid-tau index of 0.26 (\<1.0 abnormal) and a phosphorylated tau level of 73.2 pg/mL (\>61 abnormal), consistent with a diagnosis of early onset AD. There was no reported history of early onset dementia in this family (although genetic analysis was not obtained). At age 63, dramatic fluctuations in anxiety prompted further evaluation. Continuous video-EEG monitoring demonstrated rare multifocal epileptiform discharges seen independently over the right temporal, left temporal, and bifrontal regions (\~2/hour during wakefulness and \~12/hour during sleep). Bilateral FO electrode recordings demonstrated frequent right mTL spikes (\~16/hour during wakefulness and up to \~190/hour during sleep). Similar to the first patient, over 95% of the spikes detected on FO electrodes were not evident on scalp EEG ([Figure 1d](#F1){ref-type="fig"}). Those that were evident on scalp EEG resembled benign epileptiform transients of sleep, previously defined as a normal variant of no pathological significance^[@R13]^ ([Figure 1e](#F1){ref-type="fig"}). A trial of levetiracetam (1000mg/day) was not tolerated due to worsening mood.

These two patients demonstrate that clinically silent mTL seizures and spikes can occur early in the course of AD, in the absence of significant scalp EEG abnormalities, and may predominate during sleep. Here, we validate a minimally invasive method to detect this activity using FO electrodes, which are safe, readily inserted percutaneously, and allow highly sensitive monitoring of mTL activity.^[@R9],[@R14],[@R15]^ The clinical utility of FO recordings in evaluating dementia patients is not yet known, though our FO recordings clearly demonstrate that scalp EEG findings greatly underestimate subcortical hyperexcitability in AD ([Figure 2](#F2){ref-type="fig"}). All mTL seizures and over 95% of mTL spikes were not evident on scalp EEG. Additional studies of AD patients with FO recordings are needed to determine whether occult mTL epileptiform abnormalities are common or rare in AD and whether they define a hyperexcitable subtype of AD with specific treatment implications.

Our findings challenge the widely held view that epilepsy occurs only as a late sequela of neurodegeneration in AD, to be treated symptomatically once clinical seizures arise. Subclinical seizures and spikes can cause significant cognitive impairments^[@R16]--[@R18]^. Vossel and colleagues found subclinical scalp EEG and/or MEG epileptiform discharges in 42% of AD patients without a history of seizures, and patients with epileptiform discharges had a faster rate of cognitive decline^[@R19]^. In our patients, mTL seizures and spikes were activated during sleep, a period critical for memory consolidation, which may further increase their pathogenic impact^[@R20]^. Activation of spikes during sleep has been described in animal models^[@R21],[@R22]^ and patients with AD^[@R19]^, and is common in focal epilepsies^[@R23]^. EEG recordings in the AD population should at minimum include sleep. When clinical seizures arise in AD, they are typically well-controlled with medication^[@R24],[@R25]^, yet it remains unclear whether early detection and treatment of subclinical spikes and seizures can prevent or slow cognitive decline in AD. Elucidation of the cognitive impact of subclinical epileptiform activity on disease trajectory, and development of novel pharmacology to treat the specific hyperexcitability of the AD brain should be a critical priority.

Online Methods {#S1}
==============

Foramen ovale electrode placement {#S2}
---------------------------------

After explaining the risks and benefits of the procedure, consent for FO electrode placement was obtained from either the patient (Patient \#1 had capacity to provide consent) or from the patient's health care proxy (Patient \#2). Placement of foramen ovale (FO) electrodes^[@R14]^ was performed in the operating room under sterile conditions, with the patient under general endotracheal anesthesia and positioned supine with neck extended and head turned away from the site of insertion. Prior to insertion, each cheek was prepped with chlorhexidine, and Lidocaine 1% was injected 2.5 cm lateral to the labial fissure. With the fluoroscope C-arm angled 45 degrees from vertical, the foramen ovale was visualized. A 16-gauge needle was initially used to pass through the skin, and a 10-gauge needle with stylet (Ad-Tech, Racine, WI) was advanced towards the foramen ovale under fluoroscopic guidance. The needle tip was placed approximately 2mm anterior to the clival line, and a lateral fluoroscopic image was taken to confirm the needle's position. The stylet was then removed, and a four-contact FO electrode (Ad-Tech, Racine, WI) was advanced through the needle under fluoroscopic guidance so that all electrode contacts were positioned beyond the tip of the needle. A lateral fluoroscopic image was taken to confirm electrode position, and the needle was gently withdrawn. The electrode was sutured to the cheek with 0 silk sutures. The same procedure was repeated to place the FO electrode on the contralateral side. After placement of both FO electrodes, anteroposterior and lateral fluoroscopic images were taken to confirm final electrode position, and sterile dressings were placed over the electrode exit site on each cheek. The patient was awakened from general anesthesia and observed in the post-anesthesia recovery room for 1 hour. A post-procedure CT head was obtained, and the patient was brought to the inpatient Epilepsy Monitoring Unit for further monitoring. While FO electrodes were in place, the patient remained on vancomycin and ceftriaxone antimicrobial prophylaxis. At the end of the investigation, prophylactic anticoagulation was held for 24 hours, and the FO electrodes were removed at the bedside.

Scalp EEG and FO electrode recordings {#S3}
-------------------------------------

Scalp electrodes were placed using the International 10--20 system with anterior temporal electrodes (T1, T2). All recordings were acquired using XLTEK hardware (Natus Medical Inc., Pleasanton CA) with data sampled at 1024 Hz. Scalp EEG and FO electrode recordings were visually interpreted as per routine clinical practice. Spike quantification was performed manually on randomly sampled, 30--60 minute segments of uninterrupted awake or asleep states.

Cognitive testing {#S4}
-----------------

The Blessed Information-Memory-Concentration test^[@R26]^ and Montreal Cognitive Assessment^[@R27]^ were administered by physicians and/or other trained personnel during Memory Disorders Unit and/or Epilepsy Clinic visits. CDR scales were assessed at each Memory Disorders Unit visit.

Laboratory testing {#S5}
------------------

CSF amyloid and tau analysis was performed by Athena Diagnostics, Marlborough, MA (ADmark Alzheimer's Evaluation).

Imaging {#S6}
-------

For patient \#1, MRI brain images were obtained with and without gadolinium contrast, on a Siemens 3T Trio scanner, with the following sequences: sagittal FLAIR, sagittal T1, axial FLAIR, axial T2, coronal FLAIR, coronal T2, axial SWI, and axial DWI. ^18^FDG-PET images were obtained on a Siemens Biograph PET/CT scanner 45 minutes after injection with 5.5mCi of ^18^F-fluorodeoxyglucose. For patient \#2, 3T MRI brain images were obtained without contrast, with the following sequences: sagittal FLAIR, sagittal T1, axial FLAIR, axial T2, coronal T1, axial GRE, and axial DWI. All scans were performed for clinical purposes and interpreted by staff neuroradiologists.

Genetic Analysis {#S7}
----------------

Informed consent was obtained from all subjects undergoing genetic analysis. Five of six siblings of Patient \#1 were enrolled in an IRB approved neurogenetics project at Baylor College of Medicine (H-13798) with informed consent. As described previously^[@R28]^, DNA extracted from peripheral blood samples was submitted for whole exome sequencing (Genet, Gaithersburg, MD). Sequencing produced more than 120× average depth of coverage per exome (median coverage = 115) per sample with \>90% of the captured bases at \>20× coverage depth. Raw sequencing reads were processed using the Codified (<https://www.scienceexchange.com/labs/codified-genomics>) annotation platform^[@R29]^. Alleles with \> 20× coverage and 40% allele fraction were considered for further analysis. The Similarity score (the proportion of the rare variants with MAF \<0.5 shared among siblings was as expected, averaging 46% and ranging between 42% and 49%. We identified on average 707 total variants per exome (range 694--739) and an average of 131 variants per exome in known disease genes (range 124--138).
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![Subclinical mTL seizures and spikes captured with FO electrodes in two AD patients. (A--C): Patient \#1. A. Skull x-rays demonstrating radiopaque FO electrodes, with lateral (left) and anterior-posterior (right) views. B. Left mTL spikes (arrowheads), without scalp EEG correlate. Calibration scale: 200uV, 1 sec. C. Electrographic seizure from the left mTL (arrow), without scalp EEG ictal correlate. Panels show continuous EEG spanning 60 seconds. Calibration scale: 150uV, 1 sec. (D--E): Patient \#2. D. Right mTL spikes (arrowheads), without scalp EEG correlate. Calibration scale: 200uV, 1 sec. E. Three types of epileptiform discharges. *Left*: Right mTL spike (arrowhead) with scalp EEG correlate resembling benign epileptiform transient of sleep (box). *Middle*: Bifrontal spike-wave on scalp EEG (box) without FO correlate. *Right*: Left temporal sharp wave on scalp EEG (box) without FO correlate. Calibration scale: 200uV, 1 sec. (B--D): Anterior-posterior bipolar montage. L Temp = left temporal (Fp1-F7, F7-T3, T3-T5, T5-O1), R Temp = right temporal (Fp2-F8, F8-T4, T4-T6, T6-O2), L ParaS = left parasagittal (Fp1-F3, F3-C3, C3-P3, P3-O1), R ParaS = right parasagittal (Fp2-F4, F4-C4, C4-P4, P4-O2), Vertex (Fz-Cz, Cz-Pz), Coronal = coronal ring (T1-T3, T3-C3, C3-Cz, Cz-C4, C4-T4, T4-T2, T2-T1), LFO = left FO (LFO1--2, LFO2--3, LFO3--4), RFO = right FO (RFO1--2, RFO2--3, RFO3--4). (E): Referential montage (C2 reference). L Hemi = left hemisphere (Fp1, F7, T1, T3, T5, F3, C3, P3, O1), Vertex (Fz, Cz, Pz), R Hemi = right hemisphere (Fp2, F8, T2, T4, T6, F4, C4, P4, O2), LFO = left FO (LFO1, LFO2, LFO3, LFO4), RFO = right FO (RFO1, RFO2, RFO3, RFO4). Contact 1 is deepest on FOs.](nihms861286f1){#F1}

![mTL spikes detected on FO electrodes are absent from scalp EEG recordings. Quantification and comparison of spike frequencies simultaneously observed on scalp EEG (SE) and FO electrodes, during wakefulness and sleep, for Patient \#1 and \#2.](nihms861286f2){#F2}
